Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is an established treatment for patients with metastatic neuroendocrine tumours (NETs), although which factors are associated with an improved overall survival (OS) remains unclear. The primary aim of this study is to determine to what extent...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinjamuri, S, Gilbert, T M, Banks, M, McKane, G, Maltby, P, Poston, G, Weissman, H, Palmer, D H, Vora, J, Pritchard, D M, Cuthbertson, D J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629418/
https://www.ncbi.nlm.nih.gov/pubmed/23492685
http://dx.doi.org/10.1038/bjc.2013.103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629418/
https://www.ncbi.nlm.nih.gov/pubmed/23492685
http://dx.doi.org/10.1038/bjc.2013.103

Ejemplares similares